FP Oncologie SRL
FP Oncologie reported total assets of 168,499 € at the end of the 2025 financial year (annual accounts filed with the NBB on 21 Apr 2026).
The score of FP Oncologie shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -63 % Total assets -23 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
FP Oncologie's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 71,779 € | ||||
| Equity | 44,543 € | ||||
| Cash | 142,346 € | ||||
| EBITDA | 94,300 € | ||||
| Total assets | 168,499 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 21 Apr 2026
- Year ended 31 Dec 2024filed on 23 Jun 2025
- Year ended 31 Dec 2023filed on 25 Jun 2024
- Year ended 31 Dec 2022filed on 02 Aug 2023
- Year ended 31 Dec 2021filed on 20 Jun 2022
FP Oncologie's financial analysis
- Solvency26.4%sector median: 65.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of FP Oncologie
FP Oncologie's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0691.729.566
- VAT number
- BE0691729566
- Peppol
- Registered · 0208:0691729566 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 05 Mar 2018
- Registered office
- 6741 Étalle
- Latest accounts
- 2025 · filed on 21 Apr 2026
- Activity
- Medical specialists activities (NACE 86220)
FP Oncologie (SRL) has been based in Étalle since 2018, active in: medical specialists activities. For 2025, it reports a net profit of 71,779 € and equity of 44,543 €; its revenue is not published. Its solvency stands at 26.4%, below the median of its sector (65.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to FP Oncologie
Companies in the same business, of comparable size and area, outside its group.
- Studes Medical specialists activities Meise · balance sheet 168,641 €
- J-M Bouttefeux, Docteur Medical specialists activities Woluwe-Saint-Pierre · balance sheet 167,644 €
- Provost Thill Medica Medical specialists activities Tournai · balance sheet 169,503 €
- MV Medecine Medical specialists activities Berchem-Sainte-Agathe · balance sheet 171,926 €
- Société Médicale Virginie d'Orio Medical specialists activities Liège · balance sheet 168,291 €
- MM Orthopedics Medical specialists activities Soignies · balance sheet 168,261 €
- Docteur Yakup Bahcivan Medical specialists activities Ans · balance sheet 168,203 €
- Dr. Jielis Visser Cardioloog Medical specialists activities Pajottegem · balance sheet 169,022 €
Frequently asked questions about FP Oncologie
What is the revenue of FP Oncologie?
FP Oncologie files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of FP Oncologie?
In Belgium, the VAT number is the company number prefixed with BE: BE0691729566 for FP Oncologie, if the company is VAT-registered. Its company number (CBE) is 0691.729.566.
Where is the registered office of FP Oncologie?
According to the CBE register, the registered office of FP Oncologie is in 6741 Étalle.
What is the equity of FP Oncologie?
At the close of the 2025 financial year, the equity of FP Oncologie amounts to 44,543 €, a solvency of 26.4% of total assets.
Who manages FP Oncologie?
The register lists 1 active mandates at FP Oncologie. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of FP Oncologie
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →